X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (65) 65
humans (59) 59
hematology (55) 55
oncology (27) 27
abridged index medicus (25) 25
leukemia, lymphocytic, chronic, b-cell - pathology (24) 24
male (21) 21
female (19) 19
leukemia, lymphocytic, chronic, b-cell - genetics (19) 19
adult (14) 14
chronic lymphocytic leukemia (14) 14
cll (14) 14
leukemia, lymphocytic, chronic, b-cell - drug therapy (14) 14
leukemia, lymphocytic, chronic, b-cell - immunology (14) 14
leukemia, lymphocytic, chronic, b-cell - metabolism (14) 14
middle aged (13) 13
animals (12) 12
chronic lymphocytic-leukemia (12) 12
aged (11) 11
b-cells (11) 11
expression (11) 11
leukemia (9) 9
signal transduction (9) 9
survival (9) 9
tumor cells, cultured (9) 9
cancer (8) 8
immunotherapy (8) 8
rituximab (8) 8
aged, 80 and over (7) 7
apoptosis (7) 7
disease progression (7) 7
hemic and lymphatic diseases (7) 7
mice (7) 7
activation (6) 6
care and treatment (6) 6
cell proliferation (6) 6
ibrutinib (6) 6
in-vitro (6) 6
lymph nodes - pathology (6) 6
microenvironment (6) 6
open-label (6) 6
t-cells (6) 6
b-lymphocytes - immunology (5) 5
drug resistance, neoplasm (5) 5
flow cytometry (5) 5
gene (5) 5
immune system diseases (5) 5
leukemia, lymphocytic, chronic, b-cell - diagnosis (5) 5
leukemia, lymphocytic, chronic, b-cell - therapy (5) 5
mutation (5) 5
proto-oncogene proteins - genetics (5) 5
research (5) 5
treatment outcome (5) 5
tumor suppressor protein p53 - metabolism (5) 5
actin (4) 4
antineoplastic agents - pharmacology (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
article (4) 4
atm (4) 4
b-lymphocytes - metabolism (4) 4
bendamustine (4) 4
blotting, western (4) 4
cd154 gene-therapy (4) 4
cd40 antigens - metabolism (4) 4
cd40 stimulation (4) 4
cells (4) 4
cells, cultured (4) 4
chromosome deletion (4) 4
chronic lymphatic leukemia (4) 4
chronic lymphocytic leukaemia (4) 4
cystic fibrosis (4) 4
cytomegalovirus - immunology (4) 4
diagnosis (4) 4
dysfunction (4) 4
fludarabine-induced apoptosis (4) 4
health aspects (4) 4
hematology, oncology and palliative medicine (4) 4
immunology (4) 4
inhibitor (4) 4
leukemia, lymphocytic, chronic, b-cell - mortality (4) 4
life sciences (4) 4
lymphocyte activation - immunology (4) 4
medicine, general & internal (4) 4
sputum (4) 4
tp53 (4) 4
trial (4) 4
tumor proteins (4) 4
tumor suppressor protein p53 - genetics (4) 4
analysis (3) 3
antibodies, monoclonal - therapeutic use (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic agents - therapeutic use (3) 3
apoptosis - drug effects (3) 3
apoptosis regulatory proteins - genetics (3) 3
b-cell receptor (3) 3
b-cll (3) 3
b-lymphocytes - cytology (3) 3
b-lymphocytes - pathology (3) 3
blood (3) 3
bone marrow - pathology (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet Oncology, ISSN 1470-2045, 01/2019, Volume 20, Issue 1, pp. 3 - 5
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 3554 - 3554
Introduction and aim. Long-lived humoral immunity, in the form of plasma cells (PC) and memory B cells, as well as most B cell malignancies, originate in the... 
Journal Article
Haematologica, ISSN 0390-6078, 2016, Volume 101, Issue 9, pp. e376 - e377
Journal Article
Expert review of hematology, 08/2018, Volume 11, Issue 8, p. 613
Chronic lymphocytic leukemia (CLL) is frequently complicated by cytopenias, either due to bone marrow infiltration or autoimmunity, resulting in autoimmune... 
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2018, Volume 378, Issue 12, pp. 1107 - 1120
In a trial involving patients with relapsed or refractory chronic lymphocytic leukemia, the BCL2 inhibitor venetoclax in combination with rituximab resulted in... 
SURVIVAL | TRIAL | MEDICINE, GENERAL & INTERNAL | INDEPENDENT PREDICTOR | 17P DELETION | TARGETING BCL2 | PLUS RITUXIMAB | TP53 MUTATION | PROGRESSION-FREE | OPEN-LABEL | MINIMAL RESIDUAL DISEASE | Recurrence | Bendamustine Hydrochloride - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Neoplasm, Residual | Young Adult | Bendamustine Hydrochloride - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Rituximab - adverse effects | Kaplan-Meier Estimate | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sulfonamides - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Treatment outcome | Chronic lymphocytic leukemia | Diagnosis | Analysis | Chronic lymphatic leukemia | Cell survival | Hematology | Leukemia | Rituximab | Clinical trials | Oncology | Chromosome deletion | Lymphatic leukemia | Patients | Cancer therapies | Chemotherapy | Clonal deletion | Lysis | Response rates | Bone marrow | Chromosomes | Drug dosages | Chromosome 17 | Neutropenia | Index Medicus | Abridged Index Medicus | Life Sciences | Cancer
Journal Article
The Lancet, ISSN 0140-6736, 02/2018, Volume 391, Issue 10121, pp. 659 - 667
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2019, Volume 381, Issue 8, pp. 788 - 789
To the Editor: In their phase 2 study, Jain et al. (May 30 issue) 1 investigated the efficacy of ibrutinib and venetoclax in previously untreated patients with... 
MEDICINE, GENERAL & INTERNAL | Bone marrow | Chronic lymphatic leukemia | Lymphatic leukemia | Leukemia | Agent orange
Journal Article
Chest, ISSN 0012-3692, 2006, Volume 130, Issue 5, pp. 1433 - 1440
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 22, pp. 2141 - 2144
To the Editor: In the phase 3 MURANO trial, Seymour et al. (March 22 issue) 1 compared the efficacy of venetoclax plus rituximab with that of bendamustine plus... 
BENDAMUSTINE | TRIAL | MEDICINE, GENERAL & INTERNAL | MULTICENTER | OPEN-LABEL | Antineoplastic Agents | Rituximab | Sulfonamides | Humans | Leukemia, Lymphocytic, Chronic, B-Cell | Bridged Bicyclo Compounds, Heterocyclic | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 2009, Volume 113, Issue 16, pp. 3801 - 3808
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2019, Volume 37, Issue 4, pp. 269 - 277
PURPOSE The MURANO study demonstrated significant progression-free survival (PFS) benefit for fixedduration venetoclax-rituximab compared with... 
BENDAMUSTINE | INDEPENDENT PREDICTOR | CLL | MULTICENTER | ONCOLOGY | BCL2 | IBRUTINIB | OPEN-LABEL | OUTCOMES | INHIBITOR | PROGRESSION
Journal Article
Journal Article
Journal Article
Clinical pharmacokinetics, ISSN 0312-5963, 06/2019
Venetoclax is a selective B-cell lymphoma-2 (BCL-2) inhibitor approved for use as monotherapy or with rituximab in patients with chronic lymphocytic leukemia... 
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 11/2010, Volume 107, Issue 44, pp. 18956 - 18960
Mice bearing a v-Myc myelocytomatosis viral oncogene homolog (c-Myc) transgene controlled by an Ig-alpha heavy-chain enhancer (iMyc Cα mice) rarely develop... 
Spleen | Chronic lymphocytic leukemia | Messenger RNA | B lymphocytes | Leukemia | Disease progression | Mice | Blood | B cell leukemia | Apoptosis | Leukemia-cell survival | Nuclear factor κ-light-chain enhancer of activated B cells | Nurselike cells | Prognostic factors | IκB kinase inhibitor | BAFF | I kappa B kinase inhibitor | TRANSLOCATIONS | nurselike cells | MULTIDISCIPLINARY SCIENCES | PHENOTYPE | nuclear factor kappa-light-chain enhancer of activated B cells | prognostic factors | GENE | DISEASE | leukemia-cell survival | LYMPHOMA | EXPRESSION | TRANSGENIC MICE | APRIL | Humans | NF-kappa B - immunology | Proto-Oncogene Proteins c-myc - immunology | Male | Mice, Transgenic | NF-kappa B - metabolism | Genes, myc | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Proto-Oncogene Proteins c-myc - metabolism | Gene Expression Regulation, Leukemic - genetics | Animals | B-Cell Activating Factor - metabolism | B-Lymphocytes - immunology | NF-kappa B - genetics | B-Cell Activating Factor - genetics | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | B-Cell Activating Factor - immunology | Female | Immunologic Memory | Proto-Oncogene Proteins c-myc - genetics | Leukemia, Lymphocytic, Chronic, B-Cell - immunology | B-Lymphocytes - metabolism | Gene Expression Regulation, Leukemic - immunology | Development and progression | Genetic aspects | B cells | Research | Health aspects | Oncogenes | Cancer | Studies | Survival analysis | Rodents | T cell receptors | Kinases | Gene expression | Cells | Index Medicus | Biological Sciences | nuclear factor κ-light-chain enhancer of activated B cells, IκB kinase inhibitor
Journal Article
Journal Article
Lancet, ISSN 0140-6736, 02/2018, Volume 391, Issue 10121, pp. 659 - 667
BACKGROUND:Bruton tyrosine kinase is a clinically validated target in mantle cell lymphoma. Acalabrutinib (ACP-196) is a highly selective, potent Bruton... 
Life Sciences | Cancer
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.